Economic burden and healthcare utilization associated with castration-resistant prostate cancer in a commercial and Medicare Advantage US patient population

References

• American Cancer Society. Cancer Facts & Figures 2008. Available at: www.cancer.org/downloads/STT/2008CAFFfinalsecured.pdf. Accessed November 29, 2009.
   Google Scholar
• American Cancer Society. What are the key statistics about prostate cancer? Available at: http://www.cancer.org [Last accessed April 8, 2010].
   Google Scholar
• Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502–1512
   PubMed Web of Science ®Google Scholar
• Fosså SD, Slee PH, Brausi M, et al. Flutamide versus prednisone in patients with prostate cancer symptomatically progressing after androgen-ablative therapy: a phase III study of the European organization for research and treatment of cancer genitourinary group. J Clin Oncol 2001; 19: 62–71
   PubMed Web of Science ®Google Scholar
• Quilty PM, Kirk D, Bolger JJ, et al. A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer. Radiother Oncol 1994; 31: 33–40
   PubMed Web of Science ®Google Scholar
• Saad F, Karakiewicz P, Perrotte P. The role of bisphosphonates in hormone-refractory prostate cancer. World J Urol 2005; 2: 14–18
   Google Scholar
• Tannock IF, Osoba D, Stockler MR, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 1996; 14: 1756–1764
   PubMed Web of Science ®Google Scholar
• James ND, Bloomfield D, Luscombe C. The changing pattern of management for hormone-refractory, metastatic prostate cancer. Prostate Cancer Prostatic Dis 2006; 9: 221–229
   PubMed Web of Science ®Google Scholar
• Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502–1512
   PubMed Web of Science ®Google Scholar
• Rosenberg JE, Weinberg VK, Kelly WK, et al. Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients: randomized phase 2 study of ixabepilone or mitoxantrone and prednisone. Cancer 2007; 110: 556–563
   PubMed Web of Science ®Google Scholar
• James ND, Caty A, Borre M, et al. Safety and efficacy of the specific endothelin A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial. Eur Urol 2009; 55: 1112–1123
   PubMed Web of Science ®Google Scholar
• Di Lorenzo G, Figg WD, Fossa SD, et al. Combination of bevacizumab and docetaxel in docetaxel-pretreated hormone-refractory prostate cancer: a phase 2 study. Eur Urol 2008; 54: 1089–1094
   PubMed Web of Science ®Google Scholar
• Harzstark AL, Ryan CJ. Therapies in development for castrate-resistant prostate cancer. Expert Rev Anticancer Ther 2008; 8: 259–268
   PubMed Web of Science ®Google Scholar
• US Department of Labor, Bureau of Labor Statistics. Consumer Price Index. Chained Consumer Price Index for all urban consumers (C–CPI–U) 1999-2008, Medical Care. Series ID: SUUR0000SAM. Available at: http://data.bls.gov/cgi-bin/surveymost?su [Last accessed June 9 2008].
   Google Scholar
• Sherman EJ, Pfister DG, Ruchlin HS, et al. The Collection of Indirect and Nonmedical Direct Costs (COIN) form: a new tool for collecting the invisible costs of androgen independent prostate carcinoma. Cancer 2001; 91: 841–853
   PubMed Web of Science ®Google Scholar
• Krupski TL, Foley KA, Baser O, et al. Healthcare cost associated with prostate cancer, androgen deprivation therapy and bone complications. J Urol 2007; 178: 1423–1428
   PubMed Web of Science ®Google Scholar
• Wilson LS, Tesoro R, Elkin EP, et al. Cumulative cost pattern comparison of prostate cancer treatments. Cancer 2007; 109: 518–527
   PubMed Web of Science ®Google Scholar
• Krahn MD, Zagorski B, Laporte A, et al. Healthcare costs associated with prostate cancer: estimates from a population-based study. BJU Int 2010; 105: 338–346
   PubMed Web of Science ®Google Scholar
• Penson DF, Moul JW, Evans CP, et al. The economic burden of metastatic and prostate specific antigen progression in patients with prostate cancer: findings from a retrospective analysis of health plan data. J Urol 2004; 171: 2250–2254
   PubMed Web of Science ®Google Scholar
• Emmenegger U, Ko YJ. PSA-based treatment response criteria in castration-resistant prostate cancer: promises and limitations. Can Urol Assoc J 2009; 3: 375–376
   PubMed Web of Science ®Google Scholar
• Dawson N, Payne H, Battersby C, et al. Health-related quality of life in pain-free or mildly symptomatic patients with metastatic hormone-resistant prostate cancer following treatment with the specific endothelin A receptor antagonist zibotentan (ZD4054). J Cancer Res Clin Oncol: published online 14 Apr 2010, doi:10.1007/s00432-010-0864-1.
   Google Scholar
• Lindqvist O, Rasmussen BH, Widmark A. Experiences of symptoms in men with hormone refractory prostate cancer and skeletal metastases. Eur J Oncol Nurs 2008; 12: 283–290
   PubMed Web of Science ®Google Scholar
• Maffezini M. Highlighting unmet needs: real patients, difficult choices. Eur Urol 2008; 9: 4–12
   Google Scholar